Biomarkers and Diagnostic Thresholds for Congenital Hyperinsulinism
Clinical Endocrinology · 2025
DOI: 10.1111/cen.15137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology, 2025. Verfasst von Grace Petkovic und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Endocrinology, Alder Hey Children's Hospital, Liverpool, UK. Hauptthemen laut MEDLINE: Congenital Hyperinsulinism, C-Peptide, Biomarkers. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Context
Congenital Hyperinsulinism (CHI) is associated with inappropriately high levels of C‐peptide in the context of hypoglycemia.
Objective
We aimed to better clarify a diagnostic threshold value of C‐peptide for children presenting with CHI.
Design
This was a retrospective case‐control analysis, examining all hypoglycemia screens, undertaken between 2009 and 2019 at a quaternary paediatrics unit. Plasma C‐peptide, insulin, free fatty acid (FFA) and B‐hydroxybutyrate (BHOB) concentrations in children diagnosed with CHI were compared with concentrations in children diagnosed with other conditions. Patients All patients requiring hypoglycaemic screens at the quaternary children's hospital were analysed.
Results
Median [C‐peptide] were statistically significantly different between CHI (147) and non‐CHI (72) patients, p < 0.05. The Youden Index indicated that a [C‐peptide] value of 291.5 pmol/L would give the greatest optimization of sensitivity (82%) and specificity (99%) for detecting CHI. Median [insulin] differed significantly between the cohorts with a level of 64 pmol/L for CHI patients compared with 0 pmol/L with non‐CHI patients ( p < 0.01). Median [BOHB] was 0 μmol/L in CHI patients as compared with 2378 μmol/L for non‐CHI patients ( p < 0.01). Median [FFA] levels were 1910 μmol/L in the non‐CHI cohort, compared with 0 in the CHI cohort ( p < 0.01).
Conclusions
This study suggests that a C‐peptide concentration greater than 291.5 pmol/L is diagnostic of CHI in children. C‐peptide appears to offer the greatest utility as a biochemical diagnostic test for CHI and could be prioritised for laboratory analysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatric Endocrinology, Alder Hey Children's Hospital, Liverpool, UK.
- Department of Paediatrics, Lancashire Teaching Hospitals, Preston, UK.
- Department of Clinical Biochemistry, Alder Hey Children's Hospital, Liverpool, UK.
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Petkovic, G., Park, J., Collingwood, C., Senniappan, S., & Didi, M. (2025). Biomarkers and Diagnostic Thresholds for Congenital Hyperinsulinism. Clinical Endocrinology. https://doi.org/10.1111/cen.15137
Vancouver
Petkovic G, Park J, Collingwood C, Senniappan S, Didi M. Biomarkers and Diagnostic Thresholds for Congenital Hyperinsulinism. Clinical Endocrinology. 2025. doi:10.1111/cen.15137
BibTeX
@article{Petkovic2025,
author = {Petkovic, Grace and Park, Julie and Collingwood, Catherine and Senniappan, Senthil and Didi, Mohammed},
title = {Biomarkers and Diagnostic Thresholds for Congenital Hyperinsulinism},
journal = {Clinical Endocrinology},
year = {2025},
doi = {10.1111/cen.15137}
}
EUVIMED